Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Angitia raises $130M to challenge Amgen with bone-building bispecifics

Angitia raises $130M to challenge Amgen with bone-building bispecifics

  • February 5, 2026

Angitia Biopharmaceuticals has unveiled its second mega-round in 14 months, revealing a $130 million series D financing that positions the biotech to take three bone disease prospects deeper into the clinic.

Leave A Comment

Fields (*) Mark are Required